03839.HK announced that on May 11, 2022, the company's non-wholly owned subsidiary, Pucheng CP, signed a framework agreement with the target company and its controlling shareholders on the possible subscription and purchase of majority interests in the target company. The target company is established in accordance with Chinese law, mainly engaged in the development and production of veterinary drugs. Possible transactions are subject to, among other things, the satisfaction of Pucheng CP University with the due diligence results of the target company and the signing of the final agreement.